NephroGenex (OTCMKTS:NRXGQ) Stock Price, News, Analysis & History

$0.0028 0.00 (0.00 %)
(As of 03/23/2018 01:34 AM ET)
Previous Close$0.00
Today's Range$0.00 - $0.00
52-Week Range$0.00 - $0.21
Volume2,000 shs
Average Volume26,223 shs
Market Capitalization$36,250.00
P/E Ratio0.00
Dividend YieldN/A

About NephroGenex (OTCMKTS:NRXGQ)

NephroGenex logoNephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.

Receive NRXGQ News and Ratings via Email

Sign-up to receive the latest news and ratings for NRXGQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drugs - Generic


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio-0.00120689655172414
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPS($2.32)
Net IncomeN/A
Net MarginsN/A
Return on Equity-211.97%
Return on Assets-105.90%


Outstanding Shares12,950,000

NephroGenex (OTCMKTS:NRXGQ) Frequently Asked Questions

What is NephroGenex's stock symbol?

NephroGenex trades on the OTCMKTS under the ticker symbol "NRXGQ."

How were NephroGenex's earnings last quarter?

NephroGenex Inc (OTCMKTS:NRXGQ) issued its quarterly earnings results on Wednesday, November, 11th. The healthcare company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.12. View NephroGenex's Earnings History.

Where is NephroGenex's stock going? Where will NephroGenex's stock price be in 2018?

1 Wall Street analysts have issued 1-year target prices for NephroGenex's stock. Their forecasts range from $17.50 to $17.50. On average, they expect NephroGenex's share price to reach $17.50 in the next twelve months. View Analyst Ratings for NephroGenex.

Who are some of NephroGenex's key competitors?

Who are NephroGenex's key executives?

NephroGenex's management team includes the folowing people:

  • John P. Hamill CPA, Chief Executive Officer, Chief Financial Officer

Has NephroGenex been receiving favorable news coverage?

Headlines about NRXGQ stock have trended somewhat positive this week, according to Accern. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. NephroGenex earned a news sentiment score of 0.17 on Accern's scale. They also gave media stories about the healthcare company an impact score of 45.48 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of NephroGenex?

Shares of NRXGQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NephroGenex's stock price today?

One share of NRXGQ stock can currently be purchased for approximately $0.00.

How big of a company is NephroGenex?

NephroGenex has a market capitalization of $36,250.00.

How can I contact NephroGenex?

NephroGenex's mailing address is PO Box 400, JAMISON, PA 18929-0400, United States. The healthcare company can be reached via phone at +1-609-5538887.

MarketBeat Community Rating for NephroGenex (NRXGQ)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  116
MarketBeat's community ratings are surveys of what our community members think about NephroGenex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NephroGenex (OTCMKTS:NRXGQ) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.50$17.50$17.50$17.50
Price Target Upside: 624,900.00% upside12,391.08% upside12,391.08% upside12,391.08% upside

NephroGenex (OTCMKTS:NRXGQ) Consensus Price Target History

Price Target History for NephroGenex (OTCMKTS:NRXGQ)

NephroGenex (OTCMKTS:NRXGQ) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
3/29/2017FBR & CoReiterated RatingOutperform$17.50View Rating Details
4/15/2016Rodman & RenshawReiterated RatingNeutralView Rating Details
4/8/2016HC WainwrightDowngradeBuy -> NeutralView Rating Details
(Data available from 3/23/2016 forward)


NephroGenex (OTCMKTS:NRXGQ) Earnings History and Estimates Chart

Earnings by Quarter for NephroGenex (OTCMKTS:NRXGQ)

NephroGenex (OTCMKTS NRXGQ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/11/2015Q315($0.65)($0.53)ViewListenView Earnings Details
8/12/2015Q215($0.56)($0.72)ViewListenView Earnings Details
5/13/2015Q115($0.62)($0.58)ViewN/AView Earnings Details
3/24/2015Q414($0.58)($0.60)ViewN/AView Earnings Details
11/12/2014Q314($0.46)($0.50)ViewN/AView Earnings Details
8/11/2014($0.24)($0.61)ViewN/AView Earnings Details
5/14/2014Q114($0.37)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


NephroGenex (OTCMKTS:NRXGQ) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for NephroGenex (OTCMKTS:NRXGQ)

No dividend announcements for this company have been tracked by

Insider Trades

NephroGenex (OTCMKTS NRXGQ) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for NephroGenex (OTCMKTS:NRXGQ)

NephroGenex (OTCMKTS NRXGQ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/6/2015Ventures V L.P. RhoMajor ShareholderSell273,860$10.58$2,897,438.80View SEC Filing  
11/25/2014Bob PetersonVPBuy2,000$4.20$8,400.00View SEC Filing  
2/14/2014Robert R SeltzerDirectorBuy790,000$12.00$9,480,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


NephroGenex (OTCMKTS NRXGQ) News Headlines

Comparing Mylan (MYL) & NephroGenex (NRXGQ)Comparing Mylan (MYL) & NephroGenex (NRXGQ) - December 18 at 1:46 PM
Mylan (MYL) & NephroGenex (NRXGQ) Critical ContrastMylan (MYL) & NephroGenex (NRXGQ) Critical Contrast - December 14 at 11:06 PM
Head-To-Head Comparison: NephroGenex (NRXGQ) vs. Mylan (MYL)Head-To-Head Comparison: NephroGenex (NRXGQ) vs. Mylan (MYL) - December 13 at 3:50 AM
NephroGenex (NRXGQ) and Mylan (MYL) Financial SurveyNephroGenex (NRXGQ) and Mylan (MYL) Financial Survey - December 7 at 7:30 PM
NephroGenex (NRXGQ) versus Mylan (MYL) Head to Head ReviewNephroGenex (NRXGQ) versus Mylan (MYL) Head to Head Review - December 3 at 8:14 AM
NephroGenex (NRXGQ) and Allergan (AGN) Critical ContrastNephroGenex (NRXGQ) and Allergan (AGN) Critical Contrast - December 2 at 5:54 PM
Head to Head Survey: Mylan (MYL) vs. NephroGenex (NRXGQ)Head to Head Survey: Mylan (MYL) vs. NephroGenex (NRXGQ) - November 30 at 1:28 AM
Head to Head Review: Mylan (MYL) and NephroGenex (NRXGQ)Head to Head Review: Mylan (MYL) and NephroGenex (NRXGQ) - November 29 at 7:28 PM
Comparing Mylan (MYL) and NephroGenex (NRXGQ)Comparing Mylan (MYL) and NephroGenex (NRXGQ) - November 28 at 11:40 AM
Analyzing Mylan N.V. (MYL) and NephroGenex (NRXGQ)Analyzing Mylan N.V. (MYL) and NephroGenex (NRXGQ) - November 21 at 11:20 AM
Allergan PLC. (AGN) & NephroGenex (NRXGQ) Head-To-Head ComparisonAllergan PLC. (AGN) & NephroGenex (NRXGQ) Head-To-Head Comparison - November 19 at 7:22 AM
Financial Review: NephroGenex (NRXGQ) vs. Mylan N.V. (MYL)Financial Review: NephroGenex (NRXGQ) vs. Mylan N.V. (MYL) - November 19 at 5:52 AM
NephroGenex (NRXGQ) vs. Allergan PLC. (AGN) Head to Head SurveyNephroGenex (NRXGQ) vs. Allergan PLC. (AGN) Head to Head Survey - November 17 at 5:22 AM
NephroGenex (NRXGQ) vs. Allergan PLC. (AGN) Head to Head ComparisonNephroGenex (NRXGQ) vs. Allergan PLC. (AGN) Head to Head Comparison - November 17 at 1:24 AM
Head-To-Head Survey: Allergan PLC. (AGN) vs. NephroGenex (NRXGQ)Head-To-Head Survey: Allergan PLC. (AGN) vs. NephroGenex (NRXGQ) - November 16 at 10:28 AM

SEC Filings

NephroGenex (OTCMKTS:NRXGQ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


NephroGenex (OTCMKTS:NRXGQ) Income Statement, Balance Sheet and Cash Flow Statement


NephroGenex (OTCMKTS NRXGQ) Stock Chart for Friday, March, 23, 2018

Loading chart…

This page was last updated on 3/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.